

*PIDSP 19<sup>th</sup> Annual Convention*

*February 16, 2012*

*CNS INFECTIONS :  
Spotlight on Bacterial  
Meningitis*

**MARISSA B. LUKBAN, MD, FPPS, FPNA, FCNSP**  
**University of the Philippines - College of Medicine**  
**Department of Pediatrics and Neurosciences**




# *Objectives:*

- ❖ To present the epidemiological picture of bacterial meningitis worldwide and locally (Philippine General Hospital)
- ❖ To review the clinical practice guideline on the performance of lumbar puncture in children with a first febrile seizures
- ❖ To highlight the various ancillary tests available in the diagnosis of bacterial meningitis
- ❖ To discuss the current recommendations on antibiotic management of bacterial meningitis



## Case Fatality Rates

## Bacterial Meningitis – A View of the Past 90 years (1910-2000)




Swartz, NEJM 2004



# Active Bacterial Core Surveillance

Whitney  
NEJM 2003



**Figure 1.** Rates of Invasive Pneumococcal Disease among Children under Five Years Old, According to Age and Year.



TABLE 1. Incidence of meningitis caused by *Haemophilus influenzae* type b in children aged 0 to 5 years in selected areas of the world before and after introduction of conjugate vaccines<sup>a</sup>

Geographic area (yr of comparison)	No. of cases/100,000 population	
	Prevaccination	Postvaccination
United States (1987 vs 1995)	54	<1
Canada (1985 vs 1994)	~44	<1
Brazil (1988–1996 vs 1997)	22	10
Chile (1995 vs 1998)	40	<2
Uruguay (1992–1993 vs 1995)	17–22	1
Scandinavia (1970s vs 1995)	31	<1
Austria (1991 vs 1993–1996)	11	<1
Netherlands (1970s vs 1993–1994)	22–40	0.3
Spain (1993–1995 vs 1997)	14	~0
Switzerland (1976–1990 vs 1991–1993)	25	8
United Kingdom (1991–1992 vs 1993–1994)	15	0.6
Israel (1989–1992 vs 1995)	18	<1
Australia (1991–1992 vs 1993–1994)	21	6
The Gambia (1990–1993 vs 2002)	60	0
Kenya (2000–2001 vs 2004–2005)	66	7.6
Malawi (1997–2002 vs 2005)	20–40	0
Uganda (2001 vs 2003–2006)	42	<3

Brouwer  
2010



ORIGINAL ARTICLE


## Bacterial Meningitis in the United States, 1998–2007

Michael C. Thigpen, M.D., Cynthia G. Whitney, M.D., M.P.H.,  
Nancy E. Messonnier, M.D., Elizabeth R. Zell, M.Stat., Ruth Lynfield, M.D.,  
James L. Hadler, M.D., M.P.H., Lee H. Harrison, M.D., Monica M. Farley, M.D.,  
Arthur Reingold, M.D., Nancy M. Bennett, M.D., Allen S. Craig, M.D.,  
William Schaffner, M.D., Ann Thomas, M.D., Melissa M. Lewis, M.P.H.,  
Elaine Scallan, Ph.D., and Anne Schuchat, M.D.,  
for the Emerging Infections Programs Network

- **3188 pts with Bacterial Meningitis; 466/3155 (14.8%) died**
- **31% DECREASE** in incidence comparing 1998-99 vs 2006-07
- **Median age: INCREASE** from 30.3 yrs vs 41.9 yrs
- **Most common organism: Strep Pneumoniae, Group B Strep, Neisseria, Hemophilus influenzae, Listeria**




# Frequency Distribution of Bacterial Meningitis in Philippine General Hospital 2002-2006 (5 year survey)



**HIB** **Pneumo** **Others/culture negative**



# Philippine General Hospital Department of Pediatrics Inpatient Census (2010-2011)



■ HIB ■ Pneumo ■ Others/culture negative






# Philippine General Hospital Department of Pediatrics Inpatient Census (2011)

- 116 in patient admissions with meningitis
  - 63 (54%) pts with tuberculous meningitis
  - 46 (39% ) pts with bacterial meningitis
  - 7 (6%) pts with viral/aseptic meningitis



# Philippine General Hospital Department of Pediatrics Inpatient Census (2011)

**60% are 6 months and below**  
**70.8% are less than age 1 year**



# Diagnostic Examinations

To diagnose bacterial meningitis CSF examination is mandatory. CSF culture is the “gold standard” for diagnosis and it is obligatory to obtain the in vitro susceptibility of the causative organism to rationalize treatment

Van de Beek, NEJM, 2006



# PPS/PNA/CNSP 2004

## Clinical Practice Guideline on the first Febrile Seizure

Clinical Question: Among children with a first febrile seizure, is lumbar puncture recommended to rule out meningitis

- CSF analysis is not the test that confirms the diagnosis of febrile seizure per se
- CSF analysis is the gold standard for the alternative diagnosis of meningitis

**AGE plays a crucial role in decision to do lumbar puncture**



## Local Studies on the prevalence of bacterial meningitis in children presenting with a first febrile seizure

- **Mangubat & Robles (East Avenue Medical Center)**
  - Retrospective study of 198 children aged 3 months to 6 years – **1% prevalence**
- **Dilangalen & Perez (Cotabato Regional and Medical Center)**
  - Retrospective study of 339 children – **7% prevalence**



# Local Studies on the prevalence of bacterial meningitis in children presenting with a first febrile seizure

- **San Nicolas & Lukban (Philippine General Hospital)**
  - **Prospective study on validity indices of clinical parameters in predicting lumbar puncture yield of children with febrile seizures - **11/50 (22%) abnormal CSF suggestive of meningitis****
  - **Discriminate factors in the clinical signs and symptoms that differentiate children with meningitis (70% identified)**
    - Complex febrile seizure
    - Fever of more than 3 days
    - Vomiting or drowsiness at home
    - Physician visit in past 48 hours



# Significant Clinical Parameters associated with Bacterial Meningitis

- **duration of fever of more than 3 days**
- **the presence of anorexia, vomiting and sleep disturbances**
- **a physician consult within 48 hours prior to seizures**
- **the presence of ear discharge**
- **abnormal neurologic findings like nuchal rigidity and focal signs**
- **depressed level of consciousness and**
- **occurrence of seizures at the Emergency Room.**



# Philippine Clinical Practice Guideline on the first Febrile Seizure

## RECOMMENDATION STATEMENT

**Lumbar puncture is strongly recommended for children below 18 months for a first simple febrile seizure.**


**For those children  $\geq$  18 months of age, lumbar puncture should be performed in the presence of clinical signs of meningitis (meningeal signs, sensorial changes)**





# Diagnostic Examinations: The CSF

Relationship  
between serum  
and CSF glucose  
is highly linear  
For every  
increase of 1  
mg/dl of serum  
glucose, CSF  
glucose levels  
increase by 0.56  
mg/dl (95% CI  
0.56-0.57 R2 0.94)



**Figure 1.** The Relationship between Levels of Glucose in Serum and Cerebrospinal Fluid in Children 18 Years of Age or Younger.

Ratios were calculated with the use of locally weighted scatterplot smoothing (bandwidth, 0.8) for children with serum glucose levels of 400 mg per deciliter or less.



Nigrovic,  
NEJM, 2012

# The Cerebrospinal Fluid Exam

## PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

ARTICLE

### Effect of Antibiotic Pretreatment on Cerebrospinal Fluid Profiles of Children With Bacterial Meningitis

Lisa E. Nigrovic, MD, MPH<sup>1</sup>, Richard Malley, MD<sup>2</sup>, Charles G. Macias, MD, MPH<sup>3</sup>, John T. Kanegaye, MD<sup>4</sup>, Donna M. Moro-Sutherland, MD<sup>5,6</sup>, Robert D. Schrenner, MD<sup>7</sup>, Sandra H. Schwab, MD<sup>8</sup>, Dewesh Agrawal, MD<sup>9</sup>, Karim M. Mansour, MD<sup>10</sup>, Jonathan E. Bennett, MD<sup>11</sup>, Steven J. Berkowitz, MD, MPH<sup>12</sup>, Michael M. Mahoney, MD<sup>13</sup>, Blake B. Cook, MD<sup>14</sup>, Cole M. Finkle, MD<sup>15</sup>, Paul J. Escobar, MD<sup>16</sup>

20 USA ER Departments 2001-2004

Antibiotic pretreatment = received within 72 hrs from LP

- Rates of positive gram stain did not differ
- Rates of positive CSF and blood cultures less
- Not associated with total WBC and neutrophil count
- Increased glucose and decreased protein content

**Nigrovic 2008**



# Ancillary Diagnostic Examinations

- Gram staining
- Blood Culture
- Latex Agglutination – antisera directed against capsular polysaccharide of meningeal pathogen
- PCR – presence of bacterial DNA in CSF
- Skin biopsy
- Serum inflammatory markers
  - Increased serum procalcitonin
  - Increased C reactive protein



Pathogen	Sensitivity (%) <sup>a</sup>			
	Blood culture	CSF Gram stain	Latex agglutination test <sup>b</sup>	PCR
<i>Haemophilus influenzae</i>	25–90	25–65	78–100	72–92
<i>Streptococcus pneumoniae</i>	60–90	69–93	59–100	61–100
<i>Neisseria meningitidis</i>	40–60	30–89	22–93	88–94
<i>Listeria monocytogenes</i>	10–75	10–35	NA	NA
<i>Streptococcus agalactiae</i>	80–85	80–90	NA	NA
<i>Streptococcus pyogenes</i>	60–65	66–73	NA	NA
<i>Streptococcus suis</i>	50	50	NA	99
<i>Staphylococcus aureus</i>	75–100	20–44	NA	NA

**Sensitivities of various diagnostic tests to determine microbial etiologies of patients with community acquired bacterial meningitis**

**Brouwer 2010**



# Prognostic Factors related to Sequelae and Poor Outcome

- Presence of seizures
- Low CSF glucose
- High CSF protein
- Absence of rash
- Positive blood culture
- Etiology – Pneumococcal and Meningococcal



Vasilopoulou, Greek Meningitis Registry  
BMC Infectious Disease 2011

# RECOMMENDATIONS ON TREATMENT

- Based on subgroups according to age and common organisms
- Guided by prevailing antibiotic susceptibility and resistance in the region
- Generics Law
- Clinical setting
  - Malnutrition
  - Finances
  - Access to vaccination



CLINICAL SUBGROUP	EMPIRIC THERAPY	PREDOMINANT ORGANISMS
NEONATE, EARLY ONSET	Ampicillin 150 mg/kg/day [q8h] plus Gentamicin 5mg/kg/day [q12h] or Cefotaxime 100-150mg/kg/day [q8-12] or Ceftriaxone 80-100mg/kg/day [q12-24h]	S. Agalactiae, E. Coli, Listeria Monocytogenes
NEONATE, LATE ONSET	Ampicillin 200mg/kg/day [q6-8h] plus Gentamicin 7.5 mg/kg/day [q 8h] or Cefotaxime 150-200 mg/kg/day [q6-8h]	S. Agalactiae, L. monocytogenes , Gram negative bacilli
INFANTS AND CHILDREN	Cefotaxime 225-300 mg/kg/day [q6-8h] or Ceftriaxone 80-100 mg/kg/day [q12-24h] plus vancomycin 60mg/kg/day [q6h]* (if with high cephalosporin resistance)	S. Pneumoniae, N. meningitidis



<b>CLINICAL SUBGROUP</b>	<b>EMPIRIC THERAPY</b>	<b>PREDOMINANT ORGANISMS</b>
<b>ADULTS</b>	Expanded spectrum cephalosporin plus Vancomycin 30–60 mkday [q8-12h] *	Strep Pneumoniae, Neisseria Meningitidis
<b>ELDERLY AND IMMUNO-COMROMISED</b>	Expanded spectrum cephalosporin plus ampicillin 12g/day [q4h] plus Vancomycin 30 60mkday [q 8-12h]*	S. Pneumoniae, N. Meningitidis L. Monocytogenes
<b>COMMUNITY ACQUIRED RECURRENT</b>	Expanded spectrum cephalosporin plus Vancomycin 30–60 mkday [q 8-12h]*	S. Pneumoniae, N. Meningitidis, H. Influenzae
<b>NOSOCOMIAL</b>	Vancomycin 30-45 mkday [q 8-2] plus Ceftazidime 6g/day [q 8h] or Meropenem 6g/day [q 8h]	S. Aurerus, S Epidermidis, aerobic gram negative bacilli





MICROORGANISM	STANDARD THERAPY	ALTERNATIVE THERAPY
HEMOPHILUS INFLUENZAE		
B LACTAMASE (-)	Ampicillin	Ceftriaxone/Cefotaxime; Cefipime; Chloramphenicol; Aztreonam; Fluroquinolone
B LACTAMASE (+)	Ceftriaxone/ Cefotaxime	Cefipime; Chloramphenicol; Aztreonam; Fluroquinolone
BLNAR	Ceftriaxone/ Cefotaxime plus Meropenem	Ceftriaxone/Cefotaxime plus Fluroquinolone
		Brouwer 2010



<b>MICROORGANISM</b>	<b>STANDARD THERAPY</b>	<b>ALTERNATIVE THERAPY</b>
<b>STREPTOCOCCUS PNEUMONIAE</b>		
<b>PENICILLIN MIC &lt;0.1 UG/ML</b>	<b>Penicillin G or Ampicillin</b>	<b>Ceftriaxone/ Cefotaxime; Chloramphenicol</b>
<b>PENICILLIN MIC 0.1-1.0 UG/ML</b>	<b>Ceftriaxone/ Cefotaxime</b>	<b>Meropenem; Cefipime</b>
<b>PENICILLIN MIC &gt;2.0UG/ML</b>	<b>Vancomycin plus third gen cephalosporin</b>	<b>Ceftiaxone/ Cefotaxime plus moxiloxacin</b>
<b>STREPTOCOCCUS PYOGENES</b>	<b>Penicillin</b>	<b>Ceftriaxone/ Cefotaxime</b>
<b>STREPTOCOCCUS AGALACTIAE</b>	<b>Ampicillin or Penicillin G (may need to add aminoglycoside)</b>	<b>Ceftriaxone/ Cefotaxime</b>



<b>MICROORGANISM</b>	<b>STANDARD THERAPY</b>	<b>ALTERNATIVE THERAPY</b>
<b>NEISSERIA MENINGITIDIS</b>		
<b>PENICILLIN MIC &lt; 0.1 UG/ML</b>	<b>Penicillin G or Ampicillin</b>	<b>Ceftriaxone/ Cefotaxime; Chloramphenicol</b>
<b>PENICILLINE MIC 0.1-1 UG/ML</b>	<b>Ceftriaxone/ Cefotaxime</b>	<b>Chloramphenicol; Fluoroquinolone; Meropenem</b>



<b>MICROORGANISM</b>	<b>STANDARD THERAPY</b>	<b>ALTERNATIVE THERAPY</b>
<b>STAPHYLOCOCCUS AUREUS</b>		
<b>METHICILLIN SENSITIVE</b>	<b>Oxacillin or nafcillin</b>	<b>Vancomycin, Meropenem, Linezolid, Daptomycin</b>
<b>METHICILLIN RESISTANT</b>	<b>Vancomycin</b>	<b>Trimethoprim-Sulfa; Linezolid; Daptomycin</b>
<b>STAPHYLOCOCCUS EPIDERMIDIS</b>	<b>Vancomycin</b>	<b>Linezolid</b>



# Vital Role of Pediatricians

- ❑ There remains a lot to be done to replicate the success of high-income countries in decreasing the incidence of bacterial meningitis thru wide spread vaccination in resource-poor countries like the Philippines.
- ❑ There is a need for local government initiatives to make vaccinations more accessible to all beyond the EPI program.



# Vital Role of Pediatricians

**□ The pediatrician is strategically situated as he/she can act as an advocate for the prevention of meningitis and is the key to averting the disastrous complications of this disease thru early recognition and appropriate management.**



*Thank you*

